Transasia Bio-medicals’ International Hematology Range Backed By European R&d Is Now In Chandigarh

By Author: Anurag David
Total Articles: 473
Comment this article

Press release for immediate publication

Transasia Bio-Medicals’ international hematology range backed by European R&D is now in Chandigarh; eyes 300 crores in FY2020-21 from hematology in Indian market
Among India’s top 5 cities in per capita income, Chandigarh is a natural market for European technology; priced 25% below comparable options, new range to make world-class diagnostics affordable for masses

Chandigarh, April 27, 2019: Transasia Bio-Medicals Ltd., India's No. 1 In-vitro Diagnostic (IVD) Company and among the leading global players focused on emerging markets, today as part of its 40th anniversary celebration announced that its international hematology range, is now available in Chandigarh. Backed by European R&D, the 3-Part Differential Analyzer (3PDA) to 5-Part Differential Analyzer (5PDA) fully automated haematology analyzers, reagents and controls include a number of features to help institutions, clinicians and lab technologists offer accurate diagnosis. Manufactured by Erba Lachema (100% owned subsidiary of Transasia) in Europe, the H 360, H 560 and ELite 580 hematology analyzers ...
... are widely used in the European and global market. Hematology analyzers are extensively used in patient and research settings to count and characterize blood cells for disease detection and monitoring. Basic analyzers return a complete blood count (CBC) with a three-part differential white blood cell (WBC) count. Sophisticated analyzers measure cell morphology and can detect small cell populations to diagnose rare blood conditions.
In addition to the routine parameters, the new hematology range offers additional parameters such as Platelet Large Cell Ratio (PLCR) and Platelet Large Cell Concentration (PLCC) that are reported by advanced automated haematology analyzers to add more insight to the possible causes of abnormal platelet counts. The instruments thus become particularly relevant for Chandigarh, since there is a huge influx of rural masses from Himachal Pradesh and Punjab. It has been observed that a majority of these patients suffer from anemia, thalassemia and other hemoglobinopathies.
Addressing the media, Suresh Vazirani, Chairman and Managing Director, Transasia Bio-Medicals Ltd., said, “We are glad to be introducing our hematology range, here today. Chandigarh has established itself as one of the top places in India offering quality healthcare services. The Post Graduate Institute of Medical Education and Research (PGIMER), with its strong academic faculty, is one of the most premium medical institutes of India. Apart from this, in the last 5 years alone, Punjab Health Systems Corporation (PHSC), has done an excellent job of ensuring the availability of routine blood tests in all districts and rural areas by providing the latest biochemistry, hematology and ELISA analyzers in diagnostic centres. Also, the Government Multi Specialty Hospital, the oldest in the city, caters to a huge patient base. Transasia shares a long-standing association with both these institutes, with a majority of our instruments of different specialties installed at these places. Having among the highest per capita income, people of Chandigarh, are willing to spend on

technology and automation for better healthcare facilities. Thus making it the most relevant market for Transasia to introduce its European technology.”
“As per industry reports in 2018, India's medical devices industry is pegged at a $5.2 billion (Rs. 35,097.40 crore), most of which is imported. It is players like Transasia who are at the forefront of changing it and driving Make in India,” he further added.
India ranks 145th among 176 countries on the quality and accessibility of healthcare parameter. Limited access to quality medical infrastructure, including skilled manpower and technologies have been the pain points of over 70% of Indians who live in smaller towns and rural areas. Transasia has been focusing on indigenous development & technology adoption which facilitates affordable diagnostics through domestic manufacturing.
Talking about the newly launched range, Dr. Preet Kaur, M.D. Pathology, Business Unit Head, Transasia, said, “Accepted world-over for their quality, precision and ease-of-operation, the Erba range of hematology products will increase the adoption of automated hematology testing among Indian diagnostic labs. The range provides holistic solutions for clinical testing in general and targeted diagnostics which is an added advantage for pediatric and geriatric population. Other unique features include flagging of abnormal samples, RFID, large colored LCD touch screen, customizable reporting formats, ability to connect to a Laboratory Information System (LIS) for result output and ready-to-use reagents that are cyanide free and environment-friendly. By addressing many challenges that labs and pathologists face, Transasia is helping healthcare professionals (HCPs) focus on giving patients the best possible care.”
About Transasia Bio-Medicals Ltd.: Founded in 1979, Transasia Bio-Medicals Ltd., India’s Leading In-vitro Diagnostic Company offers products and solutions in Biochemistry, Hematology, Coagulation, ESR, Immunology, Urinalysis, Critical Care, Diabetes Management, Microbiology and Molecular Diagnostics. Transasia provides doctors and patients with reliable, affordable and innovative Medical Diagnostic Systems, with an impressive install base of above 65,000 equipment across India. It has a vast network of the more than 250 service engineers, 400+ sales and marketing team, 23 zonal offices and 350+ distributors. It is the first Indian company to manufacture and export blood analyzers and reagents, in the 1990s. Today, Transasia’s indigenous research has resulted in development of state of the art, ‘Make in India’ products and technologies, enabling its products to be among the best in the world. All along its journey spanning more than four decades, Transasia has been recognized for its commitment to healthcare. It has been conferred ‘The Economic Times Best Brands 2019’ award, ‘India Medical Device - Export Company of the Year’ and the ‘Global Growth Company-2014’ award by the World Economic Forum amongst many others. Headquartered in Mumbai, Transasia is a part of the global Transasia-Erba group. The group has spread its footprint across USA, UK, Germany, Czech Republic, France, Italy, Russia and Turkey through various acquisitions. Transasia-Erba Group’s production sites in India, Czech Republic and USA and R&D centres in France, UK, India and Czech Republic form a hub for indigenous manufacturing of world class deliverables. Today, the group serves millions across 100 countries. For further information, kindly visit www.erbamannheim.com
For editorial queries only contact Anurag of PRHUB @ 9322501136/anurag@prhub.com.